Skip to content

Clinical trials

Phase 1/2 Hodgkin Disease trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hodgkin Disease Phase: Phase 1/2 Country / region: United States Clear all

109 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20012
20022
20036
20043
20056
20062
20078
20086
20093
20104
20115
20126
20138
20146
20156
20164
20173
20183
20192
20211
20223
20243
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed74
Terminated16
Active, not recruiting8
Recruiting5
Unknown status5
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)12
Fred Hutchinson Cancer Center9
M.D. Anderson Cancer Center8
Columbia University4
Memorial Sloan Kettering Cancer Center4
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins4
University of Washington4
Bristol-Myers Squibb3
Mayo Clinic3
Northwestern University3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hodgkin Disease109
Lymphoma, Non-Hodgkin62
Lymphoma44
Leukemia, Lymphocytic, Chronic, B-Cell37
Lymphoma, Large B-Cell, Diffuse37
Lymphoma, Follicular36
Lymphoma, Mantle-Cell36
Multiple Myeloma33
Precursor Cell Lymphoblastic Leukemia-Lymphoma33
Burkitt Lymphoma30

Trials

Showing 1 to 25 of 109. Each trial links to its page on Pharma Observatory.

9 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.